Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04231747 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.

NCT NCT04231747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Phase
Phase 1
Overall status
Completed
Start date
May 21, 2020
Completion date
February 1, 2024
Enrollment
24 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

agressive lymphoma, diffuse-large b-cell lymphoma (dlbcl), lymphoma non-hodgkin